Paper Details

  1. Home
  2. Paper Details

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.

Author: BarriosCarlos, Carrera SouzaVinicius, CronembergerEduardo Henrique, Dos Santos MartinsSuelen Patricia, FayAndré, HerchenhornDaniel, MalufFernando Cotait, Mavignier CarcanoFlavio, Nunes FilhoPaulo R S, PeixotoFábio, Queiroz MunizDavid, SantosTelma, SchutzFábio, SmaletzOren, WerutskyGustavo, ZaffaroniFacundo

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study explores the potential of abiraterone acetate with prednisone (AAP) and apalutamide, both alone and in combination, as hormonal therapies for advanced prostate cancer. The researchers hypothesize that these treatments may be effective in reducing castration-associated side effects, such as sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk.
Paper Details　
Original Abstract of the Article :
Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients' quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with predniso...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533731/

データ提供：米国国立医学図書館（NLM）

Seeking a Balance: Optimizing Prostate Cancer Treatment

Prostate cancer, a common condition affecting men, often requires testosterone suppression as a standard treatment. However, this approach can lead to undesirable side effects, such as sexual dysfunction and increased cardiovascular risk. This research investigates the potential of combining different hormonal therapies to achieve effective cancer control while minimizing side effects. The study focuses on two promising agents, abiraterone acetate and apalutamide, and their potential for use alone or in combination to provide targeted therapy. The researchers aim to find a treatment regimen that effectively suppresses testosterone while minimizing the negative impact on patients' overall health and well-being.

Precision Treatment: Tailoring Therapies to Individual Needs

The study's findings suggest that combining abiraterone acetate and apalutamide may be a promising strategy for treating prostate cancer. This approach could offer a more personalized treatment plan, potentially reducing the need for traditional castration and its associated side effects. This aligns with the growing trend towards precision medicine, where treatments are tailored to individual patients' characteristics and needs.

Improving Quality of Life: Minimizing Side Effects and Empowering Patients

The research emphasizes the importance of improving quality of life for prostate cancer patients. By finding a treatment regimen that effectively combats the cancer while minimizing side effects, we can empower patients to live healthier and more fulfilling lives. This study highlights the need for ongoing research and development in the field of prostate cancer treatment, aiming to create personalized therapies that balance effectiveness with patient well-being.

Dr.Camel's Conclusion

Imagine navigating a challenging desert landscape, with obstacles and potential dangers lurking around every corner. Treating prostate cancer can feel similar, with the need to balance effectiveness with minimizing side effects. This research provides a compass for navigating this terrain, exploring innovative approaches to achieving optimal treatment outcomes for patients.

Date :
  1. Date Completed 2019-12-11
  2. Date Revised 2023-10-11
Further Info :

Pubmed ID

31122212

DOI: Digital Object Identifier

PMC6533731

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.